Find Roxadustat manufacturers, exporters & distributors on PharmaCompass

Roxadustat

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

20 API Suppliers, 3 USDMF, 1 KDMF, 3 NDC API, 19 Listed Suppliers

DEVELOPMENTS

20 Drug(s) in Development

20 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

7 Suppliers

7 Suppliers

DOSSIERs // Finished Dosage Formulations

5 Dossiers, 5 South Africa

MARKET PLACE

7 APIs

7 APIs

DIGITAL CONTENT

72 News

72 News

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

9,147

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Fg-4592, 808118-40-3, Fg4592, Roxadustat (fg-4592), Asp1517, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine

Molecular Formula

C₁₉H₁₆N₂O₅

Molecular Weight

352.3 g/mol

InChI Key

YOZBGTLTNGAVFU-UHFFFAOYSA-N

FDA UNII

X3O30D9YMX

Roxadustat is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity. Upon administration, roxadustat binds to and inhibits HIF-PHI, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism.

1 2D Structure

Roxadustat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid

2.1.2 InChI

InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)

2.1.3 InChI Key

YOZBGTLTNGAVFU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3

2.2 Other Identifiers

2.2.1 UNII

X3O30D9YMX

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Fg-4592

2. Fg4592

2.3.2 Depositor-Supplied Synonyms

1. Fg-4592

2. 808118-40-3

3. Fg4592

4. Roxadustat (fg-4592)

5. Asp1517

6. N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine

7. Asp 1517

8. 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic Acid

9. Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-

10. Asp-1517

11. X3o30d9ymx

12. Fg-4592 (asp1517)

13. Chembl2338329

14. Fg 4592

15. (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine

16. (((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic Acid

17. Evrenzo

18. 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic Acid

19. N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine

20. N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine

21. 2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic Acid

22. Roxadustat [usan:inn]

23. Unii-x3o30d9ymx

24. Roxadustatum

25. N-((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)glycine

26. Glycine, N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)-

27. 8ho

28. Evrenzo (tn)

29. Fg-4592[roxadustat]

30. Roxadustat [inn]

31. Roxadustat [jan]

32. Roxadustat [usan]

33. Roxadustat(fg-4592)

34. Roxadustat [who-dd]

35. Mls006010023

36. Roxadustat (jan/usan/inn)

37. Schembl523705

38. Gtpl8454

39. Dtxsid60230644

40. Ex-a390

41. Chebi:132774

42. Bcpp000230

43. Hms3654m03

44. Amy16514

45. Bcp02523

46. Bdbm50431015

47. Fg-4592,asp1517

48. Mfcd20040519

49. S1007

50. Zinc71257465

51. Akos026674331

52. Bcp9000684

53. Ccg-268052

54. Cs-1094

55. Db04847

56. Sb16615

57. Ncgc00346527-01

58. Ncgc00346527-07

59. Ac-31003

60. As-17052

61. Hy-13426

62. Smr004701207

63. Db-075703

64. Sw219900-1

65. D10593

66. J-522733

67. Q27088611

68. 2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic Acid

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₆N₂O₅
Molecular Weight	352.3 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	352.10592162 g/mol
Monoisotopic Mass	352.10592162 g/mol
Topological Polar Surface Area	109 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	508
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

In clinical development for the treatment of anemia of chronic inflammatory disease.

Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).

5 Pharmacology and Biochemistry

5.1 Pharmacology

FG-4592 represents one of several next generation PHI that has been optimized for multiple pharmacokinetic and pharmacodynamic parameters related to erythropoiesis, including selective inhibition of HIF prolyl and asparaginyl hydroxylases, potency, iron utilization, and ADME. FG-4592 represents one of several next generation HIF-PH inhibitors designed to selectively induce the expression of genes that mediate erythropoiesis for the treatment of anemia.

5.2 ATC Code

B03XA05

B - Blood and blood forming organs

B03 - Antianemic preparations

B03X - Other antianemic preparations

B03XA - Other antianemic preparations

B03XA05 - Roxadustat

5.3 Absorption, Distribution and Excretion

Absorption

Orally active

5.4 Mechanism of Action

FG-4592 is an orally active second generation HIF-PH inhibitor. Preclinical studies show that FG-4592 increases production of endogenous erythropoietin (EPO), increases iron mobilization and utilization, and overcomes the suppressive effects of inflammation on red blood cell production.